JP2007510714A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510714A5
JP2007510714A5 JP2006538993A JP2006538993A JP2007510714A5 JP 2007510714 A5 JP2007510714 A5 JP 2007510714A5 JP 2006538993 A JP2006538993 A JP 2006538993A JP 2006538993 A JP2006538993 A JP 2006538993A JP 2007510714 A5 JP2007510714 A5 JP 2007510714A5
Authority
JP
Japan
Prior art keywords
formulation
statin
hours
transporting
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538993A
Other languages
English (en)
Other versions
JP2007510714A (ja
Filing date
Publication date
Priority claimed from US10/967,167 external-priority patent/US8987322B2/en
Application filed filed Critical
Publication of JP2007510714A publication Critical patent/JP2007510714A/ja
Publication of JP2007510714A5 publication Critical patent/JP2007510714A5/ja
Pending legal-status Critical Current

Links

Claims (12)

  1. 改変放出製剤であって、少なくとも一つの酸性安定性担体輸送スタチンまたはその薬学的に許容しうる塩の治療的有効量を含み、該少なくとも一つの酸性安定性担体輸送スタチンを、腸管内および肝内での吸収速度とほぼ同等またはそれ未満である速度で放出する製
    剤。
  2. 少なくとも一つの酸性安定性担体輸送スタチンが、アトルバスタチンである、請求項１に記載の製剤。
  3. 少なくとも一つの酸性安定性担体輸送スタチンが、ロスバスタチンである、請求項１に記載の製剤。
  4. 製剤が、
    ２時間：約４０％と同等またはそれ未満；
    ４時間：約２０％〜約８０％；および
    ６時間：約７０％を超える
    という酸性安定性担体輸送スタチン放出速度を示す、請求項１に記載の製剤。
  5. 改変放出製剤であって、少なくとも一つの大分子量担体輸送スタチンまたはその薬学的に許容しうる塩の治療的有効量および少なくとも一つの膜透過性促進剤を含み、そして該少なくとも一つの大分子量担体輸送スタチンを、腸管内および肝内での吸収速度とほぼ同等またはそれ未満である速度で放出する製剤。
  6. 少なくとも一つの大分子量担体輸送スタチンが、アトルバスタチンである、請求項５に記載の製剤。
  7. 少なくとも一つの大分子量担体輸送スタチンが、ロスバスタチンである、請求項５に記載の製剤。
  8. 製剤が、
    ２時間：約４０％と同等またはそれ未満；
    ４時間：約２０％〜約８０％；および
    ６時間：約７０％を超える
    という大分子量担体輸送スタチン放出速度を示す、請求項５に記載の製剤。
  9. 改変放出製剤であって、少なくとも一つの水溶性に乏しい担体輸送スタチンまたはその薬学的に許容しうる塩の治療的有効量を含み、ここで、溶解度改善方法が、該水溶性に乏しい担体輸送スタチンに適用され、そして該製剤が、該少なくとも一つの水溶性に乏しい担体輸送スタチンを、腸管内および肝内での吸収速度とほぼ同等またはそれ未満である速度で放出する製剤。
  10. 少なくとも一つの水溶性に乏しい担体輸送スタチンが、アトルバスタチンである、請求項９に記載の製剤。
  11. 少なくとも一つの水溶性に乏しい担体輸送スタチンが、ロスバスタチンである、請求項９に記載の製剤。
  12. 製剤が、
    ２時間：約４０％と同等またはそれ未満；
    ４時間：約２０％〜約８０％；および
    ６時間：約７０％を超える
    という水溶性に乏しい担体輸送スタチン放出速度を示す、請求項９に記載の製剤。
JP2006538993A 2003-11-04 2004-10-29 担体輸送スタチンの医薬製剤およびそれらの使用 Pending JP2007510714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51677003P 2003-11-04 2003-11-04
US10/967,167 US8987322B2 (en) 2003-11-04 2004-10-19 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
PCT/IB2004/003849 WO2005041939A1 (en) 2003-11-04 2004-10-29 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof

Publications (2)

Publication Number Publication Date
JP2007510714A JP2007510714A (ja) 2007-04-26
JP2007510714A5 true JP2007510714A5 (ja) 2007-11-29

Family

ID=34556205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538993A Pending JP2007510714A (ja) 2003-11-04 2004-10-29 担体輸送スタチンの医薬製剤およびそれらの使用

Country Status (9)

Country Link
US (2) US8987322B2 (ja)
EP (2) EP1682095B1 (ja)
JP (1) JP2007510714A (ja)
AU (1) AU2004284884A1 (ja)
CA (1) CA2543716C (ja)
ES (2) ES2500924T3 (ja)
IL (1) IL175134A0 (ja)
NO (1) NO20062432L (ja)
WO (1) WO2005041939A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
EP1849459A1 (en) * 2006-03-06 2007-10-31 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
EP2007397B1 (en) * 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
TR200800269A2 (tr) * 2008-01-15 2009-08-21 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Stabil farmasötik formülasyon ve hazırlama yöntemleri
TWI391150B (zh) * 2008-01-22 2013-04-01 Taiwan Biotech Co Ltd 腸溶性長效塗覆芯與藥物劑型及其製造方法
AU2009208610A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of HMG CoA reductase inhibitors
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4088884A (en) * 1976-01-26 1978-05-09 The United States Of America As Represented By The Secretary Of The Navy Wide aperture optical communications detector
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
EP0465096A1 (en) 1990-06-26 1992-01-08 Merck & Co. Inc. Plasma cholesterol level lowering composition
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2866400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US6881860B2 (en) * 2000-04-11 2005-04-19 Atherogenics, Inc. Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
US20020147232A1 (en) * 2000-05-26 2002-10-10 Claus Sundgreen Pharmaceutical compositions comprising desglymidodrine as an active drug substance
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
MXPA04006780A (es) 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
EP1545503A4 (en) 2002-09-03 2007-12-12 Circ Pharma Res And Dev Ltd PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATINES
AU2003267756A1 (en) 2002-09-03 2004-03-29 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use

Similar Documents

Publication Publication Date Title
JP2007510714A5 (ja)
RU2470016C2 (ru) Производное бипиразола
JP2010522208A5 (ja)
JP2008531742A5 (ja)
MX2010004788A (es) Sistema de liberacion transdermica.
TW200503786A (en) Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
JP2007528876A5 (ja)
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
JP2007511487A5 (ja)
JP2005518413A5 (ja)
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
JP2005263780A5 (ja)
WO2006085335A3 (en) Pharmaceutical composition of acid labile substances
JP2006271392A5 (ja)
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
JP2009235100A5 (ja)
JP2010535814A5 (ja)
RU2010136914A (ru) Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения
JP2010540547A5 (ja)
JP2010518086A5 (ja)
JP2006517944A5 (ja)
JP2011520903A5 (ja)
MX2007003198A (es) Bolsa soluble en agua que contiene liquido.
WO2009072334A1 (ja) 製剤用核粒子
JP2005519052A5 (ja)